jcp conference-coverage

Conference Coverage

Gold Nanoparticles’ Role in Photodynamic Therapy for Cancer Treatment

07/22/2022

Researchers highlight the importance of health care providers’ awareness of advancements and utility of photodynamic therapy as a way to provide a less invasive, more effective way to treat patients with cancer.

Researchers highlight the...

07/22/2022

Journal of Clinical Pathways

Conference Coverage

Standardizing Utilization of Biosimilars in Oncology

07/06/2022

Ellen Kurek ;

Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care.

Findings from a recent...

07/06/2022

Journal of Clinical Pathways

Conference Coverage

Efficacy of Virtual Live Education on the Knowledge of Gynecologists Caring for Patients With Ovarian Cancer

06/22/2022

Vanessa Carranza, PharmD, created an educational initiative that focused on obstetricians, gynecologists, and other health care professionals, aiming to evaluate their knowledge on PARP inhibitors in ovarian cancer, ability to identify those...

Vanessa Carranza, PharmD,...

06/22/2022

Journal of Clinical Pathways

Conference Coverage

Efficacy of Teclistamab vs Real-World Treatments for Patients with Triple-Class Exposed, Relapsed/Refractory Multiple Myeloma

06/22/2022

Ellen Kurek ;

A study presented at the 2022 ASCO Annual Meeting evaluated the comparative effectiveness of teclistamab vs treatment regimens using an external control arm from a real-world database, addressing the absence of a control arm in MajesTEC-1.

A study presented at the 2022...

06/22/2022

Journal of Clinical Pathways

Conference Coverage

06/14/2022

Ellen Kurek ;

Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...

Researchers at the 2022 ASCO...

06/14/2022

Journal of Clinical Pathways

Conference Coverage

Examining the Prevalence of Prior Authorizations for Use of PARP Inhibitors in Ovarian Cancer

06/14/2022

Ellen Kurek ;

Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.

Researchers at the 2022 ASCO...

06/14/2022

Journal of Clinical Pathways

Conference Coverage

Exploring Real-World Data on the Efficacy and Safety of Oncology Drugs

06/14/2022

Ellen Kurek ;

A study presented at the ASCO Annual Meeting aimed to establish a data collection framework of EMR-based real-world data to evaluate the effectiveness and safety of cancer drugs.

A study presented at the ASCO...

06/14/2022

Journal of Clinical Pathways

Conference Coverage

Use of Homologous Recombination Thresholds for Forecasting Response to Platinum-Based Treatment in Triple-Negative Breast Cancer

06/14/2022

Ellen Kurek ;

Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.

Researchers at ASCO conducted an...

06/14/2022

Journal of Clinical Pathways

Conference Coverage

BRCA Variants in Patients With Ovarian Cancer and the Risk of Adverse Reactions

06/10/2022

Marta Rybczynski ;

A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.

A real-world study presented at...

06/10/2022

Journal of Clinical Pathways

Conference Coverage

Treatment Patterns and Efficacy of Bruton Tyrosine Kinase Inhibitors in Patients With MCL

06/09/2022

Robert Fee ;

Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.

Retrospective multicenter chart...

06/09/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products